Tumor Necrosis Factor α (human) (rec.)

CHF 456.00
In stock
YIF-LF-P007920 µgCHF 456.00
YIF-LF-P0079A100 µgCHF 1'820.00
More Information
Product Details
Synonyms Tumor Necrosis Factor Ligand Superfamily Member 2; Cachetin
Product Type Protein
Properties
Source/Host E. coli
Sequence Human TNF-alpha (aa77-233).
Crossreactivity Human
Biological Activity The ED50 as determined by the cytolysis of murine L929cells in the presense of actinomycin D is 0.03-0.06ng/ml
MW 17.5kDa
Purity ≥98% (SDS-PAGE)
Endotoxin Content <0.05EU/µg purified protein (LAL test; Lonza).
Accession Number P01375
Formulation Liquid. In 20mM Tris, pH 8.0, 1mM EDTA, 10% Glycerol.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability After reconstitution, store at -80°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Tumor necrosis factor-a (TNF-a) is a pleiotropic pro-inflammatory cytokine produced mainly by activated macrophages and in smaller amounts by several other types of cell. TNF-a has been isolated and characterized from a large number of mammals and fish species. TNF-a is expressed in two different forms: a soluble. Mature 17kDa form and a transmembrane 26kDa form. TNF-a interacts with two distinct cell-surface receptors : Tumor necrosis factor receptor 1(TNFR1) and TNFR2. these mediate the cellular actions. The actions of TNF-a are diverse and profound involving inflammation, apoptosis, cell proliferation and the stimulation of various aspects within the immune system. TNF-a is increasingly recognized as a key regulator of lipid metabolism in adipose tissue and protein catabolism in muscle and in disease states such as cancer, Acquired Immune Deficiency Syndrome (AIDS) and obesity-related insulin resistance.

Product References

1) Wen-Xing Ding et al (2004) J.Cell. Mol. Med 8(4);445-454. 2) Sudhir Gupta (2002) Journal of Clinical Immunology 22(4);185-194. 3) Frederick W. goetz et al (2004) Developmental and comparative Immunology 28;487-497. 4) Havell, E.A. (1987) J. Immunol. 39:4225-4231.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.